*4.4.1. Comparison of brain studies*

52 Hyperthermia

Study

Liver metastasis form colorectal origin,

Rectal cancer, non-operable, , Phase II,

Metastatic brain tumors study, Phase II,

Lung carcinoma study, Phase II,

Pancreas tumor study, Phase II,

Pancreas tumor study, Phase II,

Pancreas tumor study, Phase II,

Pancreas tumor study, Phase II,

Pancreas tumor study, Phase II,

Prostate cancer study, Phase II,

Pelvic gynecological cancer studies, Phase

Liver metastasis form colorectal origin,

Phase II, retrospective

retrospective

retrospective

retrospective

retrospective

retrospective

retrospective

retrospective

retrospective

retrospective

II, retrospective

Phase II, retrospective

Number of patients

Liver metastasis 29 86

Non-advanced (WHO<III) 77 11 17 Advanced (WHO≥III) 140 14.7 88

Passive arm 53 26.5 14

Passive arm 34 6.5

1st year survival (%)

Non-small cell lung cancer meta-analysis 311 [384]

Active arm 258 67.0 15.8 21 53.4 18.1

Active arm 73 52.1 9.93 58 25.5 8.4

Cervix 38 86.8 27.6 25 63.5 20.9 Ovary 27 100 37.8 67 132.7 19.4 Uterus 9 100 61.5 62 68.5 32.0

Median overall survival (m)

Resposnding patients/ratio

(%)

22 28 [382]

65 96 [383]

15 90.0 46.2 73 48.2 16.1 [368]

61 67.2 16.4 [385],

26 46.2 11.6 [386]

30 22 [387]

107 [385]

30 31.0 41 34.4 5.6 [388],

42 52.4 12.3 [390]

13 40.0 11.9 [391]

74 [392]

18 88.9 38.8 72 53.4 7.6 [377]

Median overall survival of

responding patients (m)

Median overall survival of

non-responding

patients (m)

Reference

[160]

[389]

Some more open-label, single arm, monocentric, retrospective and intention-to-treat frame oncothermia studies were published at professional conferences, [393], [394], [395], [396], [397] as well.

The comparison of the median survivals for anaplastic astrocytoma and for glioblastoma multiform obtained by different clinics shows good correlations. Their glioblastoma multiform (WHO IV) results are ranging from 14-25.2 months median survival (weighted mean is 19.1 months), while the literature ([352], [398], [399], [400]), uses only 10.5 months weighted mean.

According to the RTOG classifications [401], we divided the patients into two groups: age under- and over-50 years. By this division in cases of glioblastoma oncothermia has 14.4 and 19 months for over and under 50 years of ages, [397]; while RTOG has 9.7 and 13.7 months, [401]; respectively. The method shows successful applications in pediatric cases as well, [402].

The results are pretty coherently above the statistical values of the large databases SEER [352] and the gold-standard radiotherapy (RT) and RT+PCV [398]. The results of oncothermia show advantages in comparison with the publications on Temozolomide [399], [400], too.

The first-year survival rates compared to SEER [352] and EUROCARE [353] databases as well as to the recent chemotherapy of Temozolomide also show significant advantages (more than 25% increase) of oncothermia.

No serious side effects were observed [403]. Patients tolerated the treatments well during the whole treatment period. Most of the patients were well relaxed, some even fell asleep during the treatment. Patients reported better quality of life, but this information was not objectively measured.

Local Hyperthermia in Oncology – To Choose or not to Choose? 55

action induces new homeostatic negative feedback. The body starts to fight against our constraints together with the disease (see Figure 47.). This controversial situation happens with classical hyperthermia, when the constrained massive temperature change is physiologically down-regulated (or at least the physiology works against it by the systemic [like blood-flow] and local [like HSP] reactions). Oncothermia disclaims the old approach, introducing a new paradigm: with the application of micro-heating, it induces considerably less physiological feedback to work against the action, and with the application of the electric field it uses such effect, for which the body has no physiological answer. With this new paradigm, oncothermia helps the natural feedback mechanisms to reestablish the

**Figure 45.** The natural healthy state is stabilized by the negative feedback loops of physiology

**Figure 46.** The disease breaks the homeostasis, so the physiology tries to compensate and correct the

healthy state (see Figure 48.).

damage

The results well indicate the feasibility and the benefit of the oncothermia showing a valid treatment potential and safe application. Oncothermia is a potential way to escape from the present impasse situation and could treat brain gliomas successfully. Question of Editorial of JAMA "Where to go from here?" [404] could be answered with the help of the oncothermia way.
